<p>Medacta Group SA reported preliminary unaudited revenue of EUR 683.8 million for the full year 2025, representing an increase of 18.5% in constant currency and 15.8% in Euro compared to the previous year. Revenue growth was recorded across all geographic markets and business lines. By segment, Hip generated EUR 270.5 million (up 11.9% in constant currency), Knee EUR 284.1 million (up 20.7%), Extremities—including Shoulder and Sportsmed—EUR 72.1 million (up 46.2%), and Spine EUR 57.0 million (up 12.2%). The acquisition of Parcus Medical in March 2025 contributed approximately 1.5% to group revenue. The company also created 258 new jobs in 2025. These figures are preliminary and unaudited, with full year results scheduled for release on 13 March 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2269966_en), on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

562600

SBIO

159898

159883

Reuters

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Medical Devices

ALPS Medical Breakthrough

China Merchants CSI All Share Medical Apparatus and Instruments ETF

SPDR S&P Health Equip

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Medacta Group reports 18.5% revenue growth in 2025